It is now a widely accepted dictum that Intellectual Property Rights (IPR), especially pharma patents, help fostering innovation and is critical in meeting unmet needs of the patients. However, the moot question still remains, what type pharmaceutical invention, should deserve market exclusivity or monopoly with overall freedom in pricing, keeping larger public health interest in mind. In line with this thinking, for quite sometime a raging global debate has brought to the fore that there are...
Balancing IPR with Public Health Interest: Brickbats, Power Play and Bouquets
B